Takeda Pharmaceutical
349 hedge funds and large institutions have $1.31B invested in Takeda Pharmaceutical in 2025 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 97 increasing their positions, 127 reducing their positions, and 43 closing their positions.
1,184% more call options, than puts
Call options by funds: $32.6M | Put options by funds: $2.54M
58% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 43
6% more funds holding
Funds holding: 330 → 349 (+19)
5% more capital invested
Capital invested by funds: $1.25B → $1.31B (+$58.6M)
0.05% less ownership
Funds ownership: 2.68% → 2.63% (-0.05%)
24% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 127
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$57.4M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$40.8M |
| 3 |
VanEck Associates
New York
|
+$16.3M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$12.6M |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$6.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$31.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25.3M |
| 3 |
Millennium Management
New York
|
-$23.8M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$22.6M |
| 5 |
Morgan Stanley
New York
|
-$18.8M |
TAK Hedge Fund Activity: Q4 2025 in Review
349 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2025, worth a combined $1.31B — up 4.7% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new TAK positions and 43 closed out — a net gain of 25 holders — while 97 added to existing stakes and 127 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $57.4M. The largest seller was Toronto Dominion Bank, cutting an estimated $31.2M.
- 349 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2025, up from 330 in Q3 2025.
- Funds reported $1.31B of Takeda Pharmaceutical stock for Q4 2025, up 4.7% quarter-over-quarter.
- 68 funds opened new Takeda Pharmaceutical positions in Q4 2025 and 43 closed out, a net change of +25 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2025 was D.E. Shaw & Co, an estimated $57.4M added.
- The largest Takeda Pharmaceutical seller in Q4 2025 was Toronto Dominion Bank, an estimated $31.2M sold.
Based on aggregated 13F filings for Q4 2025.